CClinicalTrials.gg
Status unknownNCT02518867Updated Aug 10, 2015

Motor Disability of Children With Cerebral Palsy Using Motor Transcranial Magnetic Stimulation

An interventional study of high intensity iTBS and low intensity iTBS in Cerebral Palsy, sponsored by Chang Gung Memorial Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 7 Years to 20 Years. Per ClinicalTrials.gov, last updated 2015-08-10.

Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2015), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
7 Years to 20 Years
Sex
All
01

Study summary

Transcranial magnetic stimulation (TMS) has opened new potential avenues for the treatment of neuropsychiatric diseases via the effects of modulation on neuroplasticity. Repetitive TMS (rTMS) is a non-invasive method of stimulation neural pathways in the brain of conscious subjects through the intact scalp. The investigators hypothesize that excitatory rTMS applied over the motor cortex would increase motor cortex activity and result in an increase in the inhibitory input through the corticospinal tract to the spinal cord, thus reducing alpha neuron hyperactivity and consequently clinical spasticity. In this study, the investigators will apply the stimulation on the legs motor cortex area, which can cover supplemental motor area (SMA). Therefore, not only the spasticity, but also the motor control of legs both can be modulated by stimulation. Theta burst stimulation is a condition of rTMS which was designed by the co-investigator. It has controllable, consistent, long-lasting, and powerful effects on motor cortex physiology and behavior. The investigators therefore design this protocol using theta burst stimulation on the motor cortex of the patients of cerebral palsy. The investigators expect that there would be an effect on the reduction of spasticity after rTMS on the brain of children with CP, thus improving the motor control of legs.

Read the detailed description

In this study, the investigators design 3 steps to find out the optimal condition of rTMS for the treatment and managing of motor disability of CP. The first is to find out the optimal intensity of rTMS. The second is to find out the optimal duration of rTMS and long term effects. The third is to compare the effectiveness of botulinum toxin injection, rTMS, and combined therapy (botulinum toxin injection and rTMS) for children with CP.

02

Conditions studied

  • Cerebral Palsy

Keywords

  • Cerebral palsy
  • Transcranial magnetic stimulation
03

In context

Paralysis

750 studies on the registry are indexed under Paralysis; 133 are open to participants now.

This study's planned enrollment of 90 is above the median of 30 across 537 interventional studies indexed under Paralysis.

Browse Paralysis studies →

Lead sponsor

Chang Gung Memorial Hospital is the lead sponsor of 1,064 studies on the registry; 235 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • diagnosis of mild to moderate CP with spastic diplegia or hemiplegia according to clinical criteria
  • age 7-20 years
  • no use of botulinum toxin in the past 4 months
  • no significant perceptual or communication disturbances
  • no other peripheral or central nervous system dysfunction
  • no active inflammatory or pathologic changes in lower limb joints during the previous 6 months
  • no active medical problems, such as pneumonia, upper gastrointestinal bleeding, or urinary tract infection
  • no active problems of epilepsy and EEG without epileptiform discharge
  • ability to walk 20m without walking aids, such as a cane, quadricane or walker

Exclusion criteria

Exclusion Criteria:

  • Metabolic disorders, such as inborn error of metabolism, electrolyte, and endocrine disorders.
  • Active infectious disease, such as meningitis and encephalitis.
  • Patients with active medical problems, such as pneumonia, upper gastrointestinal bleeding, or urinary tract infection.
  • Poor compliance or intolerance for the TMS therapy
  • Subjects with metallic implants or pregnancy.
  • EEG show epileptiform discharge
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    high intensity iTBS

    high intensity iTBS: 100% of active motor threshold for 3 days.

    Other: high intensity iTBS

  • Experimental
    low intensity iTBS

    low intensity iTBS: 80% of active motor threshold for 3 days.

    Other: low intensity iTBS

  • Sham comparator
    sham iTBS

    sham iTBS for 3 days.

    Other: sham iTBS

Interventions

  • Otherhigh intensity iTBS

    In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (high intensity , 100% of active motor threshold) TBS for 3 days.

    Also known as: high intensity intermittent theta burst stimulation

  • Otherlow intensity iTBS

    In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low intensity, 80% of active motor threshold) TBS for 3 days.

    Also known as: low intensity intermittent theta burst stimulation

  • Othersham iTBS

    In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment.

    Also known as: sham theta burst stimulation

06

What researchers measure

Primary outcomes

  1. Change from baseline of Kinematic analysis in post-treatment (after 3 days intervention) and one months follow up.

    Kinematic analysis for gait analysis.

    Time frame: baseline, post-treatment (after 3 days intervention), one months

07

Study locations

1 of 1 sites recruiting
  • Chang Gung Memorial Hospital
    Taoyuan, 333, Taiwan
    • Kuang-Lin Lin · Contact · lincgh@cgmh.org.tw · +886-3-3281200
    • Kuang-Lin Lin · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02518867
Lead sponsor
Chang Gung Memorial Hospital
Responsible party
Sponsor
First posted
Aug 10, 2015
Start date
Mar 2013
Primary completion
Oct 2015 (estimated)
Completion
Dec 2015 (estimated)
Last update
Aug 10, 2015

Study contacts

Kuang-Lin Lin
Contact
lincgh@cgmh.org.tw
+886-3-3281200 ext. 8200
Kuang-Lin Lin
study director · Chang Gung Memorial Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion